Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin Label May Not Need Physician Diagnosis Statement – Consultant

This article was originally published in The Tan Sheet

Executive Summary

Physician diagnosis instructions on OTC Claritin labeling would not be necessary if the second generation, non-sedating antihistamine is approved by FDA for a general hives or urticaria claim, according to William Rosenberg, MD, University of Tennessee

You may also be interested in...



Claritin OTC Approval For CIU Would Reduce Off-Label Drug Use – Schering

Failure to approve Claritin OTC for chronic idiopathic urticaria would perpetuate off-label use of non-prescription drugs to treat hives, Schering-Plough told FDA's Nonprescription Drugs Advisory Committee at a meeting in Bethesda, Md. April 22

Loratadine Clinical Trials On General Hives Suggested By NDAC Members

An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22

Loratadine Clinical Trials On General Hives Suggested By NDAC Members

An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22

Related Content

Topics

UsernamePublicRestriction

Register

PS093935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel